NRSN
NASDAQ · Biotechnology
Neurosense Therapeutics Ltd
$0.45
+0.01 (+2.26%)
Open$0.44
Previous Close$0.44
Day High$0.46
Day Low$0.44
52W High$1.98
52W Low$0.39
Volume—
Avg Volume486.6K
Market Cap16.73M
P/E Ratio—
EPS$-0.62
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+7,675.3% upside
Current
$0.45
$0.45
Target
$35.23
$35.23
$27.84
$35.23 avg
$57.14
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.58M | 1.62M | 1.28M |
| Net Income | 134.3K | 163.7K | 131.8K |
| Profit Margin | 8.5% | 10.1% | 10.3% |
| EBITDA | 233.3K | 224.5K | 177.5K |
| Free Cash Flow | 149.0K | 201.8K | 175.9K |
| Rev Growth | +15.5% | +19.0% | +13.7% |
| Debt/Equity | 0.19 | 0.18 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |